Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aimmune Therapeutics, Inc.
Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
June 30, 2022
From
Aimmune Therapeutics, Inc.
Via
Business Wire
Aimmune Therapeutics Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for up to 2 Years in the Journal of Allergy and Clinical Immunology
February 16, 2022
From
Aimmune Therapeutics, Inc.
Via
Business Wire
Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting
November 12, 2021
From
Aimmune Therapeutics, Inc.
Via
Business Wire
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.
November 05, 2021
From
Aimmune Therapeutics, Inc.
Via
Business Wire
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
August 04, 2021
From
Aimmune Therapeutics, Inc.
Via
Business Wire
Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis
June 08, 2021
From
Aimmune Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.